Abstract
New therapies based on the targeting of signal pathways (such as VHL/HIF-1) common to most renal cell carcinomas (RCC), have greatly improved the outlook for sufferers of this disease. Given the growing reputation of many microRNAs (miRNAs) as both tumor suppressors and oncogenes, the measurement and manipulation of these small nucleotides in RCC patients may provide yet another valuable advance in renal cancer diagnosis and treatment. The present review summarizes the current literature on the role of microRNAs in RCC development and progression emphasizing the interaction of specific miRNAs with both oncogenic and tumor suppressor pathways of particular importance in renal cancer.
Keywords: c-MET, cancer, hypoxia-inducible factor (HIF), mammalian target of rapamycin (mTOR), miRNA, renal cell carcinoma, vascular endothelial growth factor (VEGF), Von Hippel-Lindau protein (VHL).
Graphical Abstract
MicroRNA
Title:MicroRNAs in Renal Cell Carcinoma
Volume: 4 Issue: 1
Author(s): Donald F. Sellitti and Sonia Q. Doi
Affiliation:
Keywords: c-MET, cancer, hypoxia-inducible factor (HIF), mammalian target of rapamycin (mTOR), miRNA, renal cell carcinoma, vascular endothelial growth factor (VEGF), Von Hippel-Lindau protein (VHL).
Abstract: New therapies based on the targeting of signal pathways (such as VHL/HIF-1) common to most renal cell carcinomas (RCC), have greatly improved the outlook for sufferers of this disease. Given the growing reputation of many microRNAs (miRNAs) as both tumor suppressors and oncogenes, the measurement and manipulation of these small nucleotides in RCC patients may provide yet another valuable advance in renal cancer diagnosis and treatment. The present review summarizes the current literature on the role of microRNAs in RCC development and progression emphasizing the interaction of specific miRNAs with both oncogenic and tumor suppressor pathways of particular importance in renal cancer.
Export Options
About this article
Cite this article as:
Sellitti F. Donald and Doi Q. Sonia, MicroRNAs in Renal Cell Carcinoma, MicroRNA 2015; 4 (1) . https://dx.doi.org/10.2174/2211536604666150713105247
DOI https://dx.doi.org/10.2174/2211536604666150713105247 |
Print ISSN 2211-5366 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5374 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Omega-3 and Renal Function in Older Adults
Current Pharmaceutical Design Novel Etomidate Derivatives
Current Pharmaceutical Design Combination Therapy with Hepatocyte Growth Factor and Oseltamivir Confers Enhanced Protection Against Influenza Viral Pneumonia
Current Molecular Medicine CD47 Functionalization of Nanoparticles as a Poly(ethylene glycol) Alternative: A Novel Approach to Improve Drug Delivery
Current Drug Targets In Vitro and In Vivo Approaches for Screening the Potential of Anticancer Agents: A Review
Current Drug Discovery Technologies Bioprecursor Prodrugs: Molecular Modification of the Active Principle
Mini-Reviews in Medicinal Chemistry Prophylaxis of Cancer
Current Cancer Therapy Reviews Cancer Gene Therapy with Tissue Inhibitors of Metalloproteinases (TIMPs)
Current Gene Therapy Patent Selections:
Recent Patents on Biomarkers VEGF Inhibitors in Cancer Therapy
Current Pharmaceutical Design miR-342-5p as a Potential Regulator of HER2 Breast Cancer Cell Growth
MicroRNA The Concurrent Therapeutic Potential of Adipose-derived Mesenchymal Stem Cells on Gentamycin-induced Hepatorenal Toxicity in Rats
Current Stem Cell Research & Therapy Nucleic Acids as Therapeutic Agents
Current Topics in Medicinal Chemistry Biomarker Discovery in Clinical Proteomics: Strategies for Exposing Low Abundant Proteins
Current Proteomics Nutrigenomics: Advances, Opportunities and Challenges in Understanding the Nutrient-Gene Interactions
Current Nutrition & Food Science CRIM1, the Antagonist of BMPs, is a Potential Risk Factor of Cancer
Current Cancer Drug Targets What is the Current Role of Immunotherapy for Colon Cancer?
Reviews on Recent Clinical Trials PI3K/Akt/mTOR Pathway Inhibitors in Cancer: A Perspective on Clinical Progress
Current Medicinal Chemistry Methylenetetrahydrofolate Reductase (MTHFR): A Novel Target for Cancer Therapy
Current Pharmaceutical Design Promotion of Optimized Protein Therapy by Bioconjugation as a Polymeric DDS
Anti-Cancer Agents in Medicinal Chemistry